DMTK Stock - DermTech, Inc.
Unlock GoAI Insights for DMTK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $15.30M | $14.52M | $11.84M | $5.88M | $3.36M |
| Gross Profit | $276,000 | $647,000 | $1.27M | $-96,000 | $60,000 |
| Gross Margin | 1.8% | 4.5% | 10.8% | -1.6% | 1.8% |
| Operating Income | $-103,739,000 | $-118,165,000 | $-77,398,000 | $-35,289,000 | $-17,605,000 |
| Net Income | $-100,888,000 | $-116,683,000 | $-78,335,000 | $-36,477,000 | $-21,902,000 |
| Net Margin | -659.6% | -803.7% | -661.7% | -619.8% | -651.1% |
| EPS | $-3.09 | $-3.88 | $-2.71 | $-2.05 | $-3.13 |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 18th 2022 | Oppenheimer | Resumed | Outperform | $48 |
| June 14th 2022 | BTIG Research | Reiterated | Buy | $19← $38 |
Earnings History & Surprises
DMTKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 1, 2024 | $-0.52 | $-0.99 | -90.4% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.62 | $-0.58 | +6.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.54 | $-0.56 | -3.7% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.68 | $-0.57 | +16.2% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.95 | $-0.99 | -4.2% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.90 | $-1.02 | -13.3% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.96 | $-0.93 | +3.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.99 | $-0.96 | +3.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.02 | $-0.99 | +2.9% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.85 | $-1.01 | -18.8% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.73 | $-0.88 | -20.5% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.65 | $-0.68 | -4.6% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.54 | $-0.48 | +11.1% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.47 | $-0.49 | -4.3% | ✗ MISS |
Q1 2021 | Mar 4, 2021 | $-0.54 | $-0.48 | +11.1% | ✓ BEAT |
Q4 2020 | Nov 10, 2020 | $-0.58 | $-0.50 | +13.8% | ✓ BEAT |
Q3 2020 | Aug 5, 2020 | $-0.37 | $-0.58 | -56.8% | ✗ MISS |
Q2 2020 | May 13, 2020 | $-0.46 | $-0.53 | -15.2% | ✗ MISS |
Q1 2020 | Mar 11, 2020 | $-0.40 | $-0.08 | +80.0% | ✓ BEAT |
Q4 2019 | Nov 7, 2019 | — | $-0.80 | — | — |
Latest News
Frequently Asked Questions about DMTK
What is DMTK's current stock price?
What is the analyst price target for DMTK?
What sector is DermTech, Inc. in?
What is DMTK's market cap?
Does DMTK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DMTK for comparison